<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table6" position="float"><object-id pub-id-type="doi">10.7554/eLife.33478.012</object-id><label>Table 6.</label><caption><title>Summary of clinical grade 3 or four adverse events by randomised group</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Event</th><th valign="top">Placebo <break/>(n&#160;=&#160;41) <break/>No. patients (%) (number of events)</th><th valign="top">Aspirin 81 mg (n&#160;=&#160;39) <break/>No. patients (%) (number of events)</th><th valign="top">Aspirin 1000 mg (n&#160;=&#160;40) <break/>No. patients (%) (number of events)</th><th valign="top">P-value comparison</th></tr></thead><tbody><tr><td valign="top"><bold>All events</bold></td><td valign="top"><bold>11 (26.8%) (17)</bold></td><td valign="top"><bold>17 (43.6%) (33)</bold></td><td valign="top"><bold>9 (22.5%) (16)</bold></td><td valign="top"><bold>0.11</bold></td></tr><tr><td valign="top"><bold>Allergic events</bold> <break/>- Rash <break/>- Stevens Johnsons syndrome*</td><td valign="top"><bold>1 (2.4%) (1)</bold> <break/>1 (2.4%) (1) <break/>0</td><td valign="top"><bold>1 (2.6%) (2)</bold> <break/>0 <break/>1 (2.6%) (2)</td><td valign="top"><bold>0</bold></td><td valign="top"><bold>0.77</bold></td></tr><tr><td valign="top"><bold>Cardiac events</bold> <break/><bold>-</bold> Hypotension</td><td valign="top"><bold>0</bold></td><td valign="top"><bold>3 (7.7%) (3)</bold> <break/>3 (7.7%) (3)</td><td valign="top"><bold>1 (2.5%) (1)</bold></td><td valign="top"><bold>0.08</bold></td></tr><tr><td valign="top"><bold>Electrolyte events</bold> <break/><bold>-</bold> Hyponatraemia <break/>- Hypokalaemia</td><td valign="top"><bold>1 (2.4%) (1)</bold> <break/>1 (2.4) (1) <break/>0</td><td valign="top"><bold>4 (10.3%) (4)</bold> <break/>4 (10.3%) (4) <break/>0</td><td valign="top"><bold>3 (7.5%) (3)</bold> <break/>2 (5.0%) (2) <break/>1 (2.5%) (1)</td><td valign="top"><bold>0.31</bold></td></tr><tr><td valign="top"><bold>Gastrointestinal events</bold> <break/>- Vomiting blood <break/>- Melena</td><td valign="top"><bold>2 (4.9%) (2)</bold> <break/>2 (4.9%) (2) <break/>0</td><td valign="top"><bold>1 (2.6%) (1)</bold> <break/>1 (2.6%) (1) <break/>0</td><td valign="top"><bold>1 (2.5%) (1)</bold> <break/>0 <break/>1 (2.5%) (1)</td><td valign="top"><bold>1.00</bold></td></tr><tr><td valign="top"><bold>Hepatic events</bold> <break/>- Hepatitis</td><td valign="top"><bold>1 (2.4%) (2)</bold> <break/>1 (2.4%) (2)</td><td valign="top"><bold>1 (2.6%) (1)</bold> <break/>1 (2.6%) (1)</td><td valign="top"><bold>0</bold></td><td valign="top"><bold>0.77</bold></td></tr><tr><td valign="top"><bold>Neurological events</bold> <break/>- Hemiparesis <break/>- Paraparesis <break/>- Cranial nerve palsy <break/>- Fall in GCS&#160;&#8805;&#160;2 points for&#160;&#8805;&#160;2 days</td><td valign="top"><bold>4 (9.8%) (5)</bold> <break/>0 <break/>1 (2.4%) (1) <break/>0 <break/>2 (4.9%) (2)</td><td valign="top"><bold>9 (23.1%) (13)</bold> <break/>1 (2.6%) (1) <break/>2 (5.1%) (2) <break/>1 (2.6%) (1) <break/>5 (12.8%) (5)</td><td valign="top"><bold>3 (7.5%) (5)</bold> <break/>0 <break/>1 (2.5%) (1) <break/>0 <break/>2 (5.0%) (2)</td><td valign="top"><bold>0.11</bold></td></tr><tr><td valign="top"><bold>Respiratory events</bold> <break/>- Pneumonia <break/>- Respiratory failure</td><td valign="top"><bold>4 (9.8%) (4)</bold> <break/>0 <break/>4 (9.8%) (4)</td><td valign="top"><bold>8 (20.5%) (9)</bold> <break/>1 (2.6%) (1) <break/>8 (20.5%) (1)</td><td valign="top"><bold>4 (10.0%) (4)</bold> <break/>0 <break/>4 (10.0%) (4)</td><td valign="top"><bold>0.30</bold></td></tr><tr><td valign="top"><bold>Other events&#8224;</bold></td><td valign="top"><bold>2 (4.9%) (2)</bold></td><td valign="top"><bold>0</bold></td><td valign="top"><bold>2 (5.0%) (2)</bold></td><td valign="top"><bold>0.54</bold></td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>Event related to rifampicin, not study drug</p><p>P-values refer to Fisher&#8217;s exact test for the number of participants with at least one event.</p></fn></table-wrap-foot></table-wrap>